

U.S. PATENT DOCUMENTS

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.


<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	10/517,338
				Filing Date	December 9, 2004
				First Named Inventor	WARNAAR et al.
				Group Art Unit	1642
				Examiner Name	Catherine Joyce
Confirmation No.				2944	
Sheet	2	of	3	Attorney Docket Number	2923-672

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
CD	4	WO	93/18152	A1	CIBA Corning Diagnostics Corp.	09-16-1993	
↓	5	WO	97/41831	A1	Comell Research Foundation, Inc.	11-13-1997	
Examiner Signature	Catherine Joyce				Date Considered	6/10/07	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	10/517,338
				Filing Date	December 9, 2004
				First Named Inventor	WARNAAR et al.
				Group Art Unit	1642
				Examiner Name	Catherine Joyce
				Confirmation No.	2944
Sheet	3	of	3	Attorney Docket Number	2923-672

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>		
	6	Christianne BUSKENS et al., "Adenocarcinomas of the Gastro-esophageal junction: a comparative study of the gastric cardia and the esophagus with respect to cyclooxygenase-2 expression", Digestive Disease Week Abstracts and Itinerary Planner, Vol. 2003, 2003, page Abstract No. 850	AB		
	7	Kim A. MARGOLIN, "Interleukin-2 in the Treatment of Renal Cancer", Seminars in Oncology, Vol. 27, No. 2, April 2002, pages 194-203			
	8	Peter F.A. MULDER et al., "The Role of Adjuvant Immunotherapy in Renal Cell Carcinoma", Current Urology Reports, 2002, Vol. 3 pages 44-49			
	9	Kendall A. SMITH, "Lowest Dose Interleukin-2 Immunotherapy", Blood, Vol. 81, No. 6, March 15, 1993, pages 1414-1423			
	10	Paul M. SONDEL et al., "Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer", Cancer Research 48, May 1, 1988, pages 2561-2567			
	11	Jeff A. SOSMAN et al., "Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin", Journal of the National Cancer Institute Vol. 80, No. 18, November 16, 1988, pages 1451-1461			
	12	R. C. STEIN et al., "The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin 2", Br. J. Cancer 63, 1991, pages 275-278			
	13	J. R. TURNER et al., "MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker", Hum Pathol 1997, Jun; 28(6):740-4, PubMed Abstract	AB		
	14	M.L. NASI et al., "Treatment (tx) with daily low-dose subcutaneous (sc) interleukin-2 (IL-2) followed by monoclonal antibody R24 against GD3 ganglioside in patients (pts) with metastatic melanoma (MM)", <a href="http://www.asco.org/prof/me/html/abstracts/ms/m_1770.htm">http://www.asco.org/prof/me/html/abstracts/ms/m_1770.htm</a> , 1997	AB		
	15	Joost L. M. VISSERS et al., "The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocytes", Cancer Research 59, November 1, 1999, pages 5554-5559			
Examiner Signature				Date Considered	6/10/07

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

1390814\_1